Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Mark M. Awad(Dana-Farber Cancer Institute), Alejandro Navarro(Vall d'Hebron Hospital Universitari), Maya Gottfried(Meir Medical Center), Solange Peters(University of Lausanne), Tibor Csőszi, Parneet Cheema(University of Toronto), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Mirjana Wollner(Rambam Health Care Campus), James Chih‐Hsin Yang(National Taiwan University Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), Francesco Orlandi, Alexander Luft(Leningrad Regional Cancer Center), Mahmut Gümüş(Istanbul Medeniyet University), Terufumi Kato(Kanagawa Prefectural Hospital Organization), Gregory P. Kalemkerian(University of Michigan), Yiwen Luo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Victoria Ebiana(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hye Ryun Kim(Yonsei University), on behalf of the KEYNOTE-604 Investigators
Journal of Clinical Oncology
May 29, 2020
Cited by 749Open Access
Full Text

Abstract

PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC. METHODS Eligible patients were randomly assigned 1:1 to pembrolizumab 200 mg once every 3 weeks or saline placebo for up to 35 cycles plus 4 cycles of EP. Primary end points were progression-free survival (PFS; RECIST version 1.1, blinded central review) and overall survival (OS) in the intention-to-treat population. Objective response rate (ORR) and duration of response were secondary end points. Prespecified efficacy boundaries were one-sided P = .0048 for PFS and .0128 for OS. RESULTS Of the 453 participants, 228 were randomly assigned to pembrolizumab plus EP and 225 to placebo plus EP. Pembrolizumab plus EP significantly improved PFS (hazard ratio [HR], 0.75; 95% CI, 0.61 to 0.91; P = .0023). Twelve-month PFS estimates were 13.6% with pembrolizumab plus EP and 3.1% with placebo plus EP. Although pembrolizumab plus EP prolonged OS, the significance threshold was not met (HR, 0.80; 95% CI, 0.64 to 0.98; P = .0164). Twenty-four-month OS estimates were 22.5% and 11.2%, respectively. ORR was 70.6% in the pembrolizumab plus EP group and 61.8% in the placebo plus EP group; the estimated proportion of responders remaining in response at 12 months was 19.3% and 3.3%, respectively. In the pembrolizumab plus EP and placebo plus EP groups, respectively, any-cause adverse events were grade 3-4 in 76.7% and 74.9%, grade 5 in 6.3% and 5.4%, and led to discontinuation of any drug in 14.8% and 6.3%. CONCLUSION Pembrolizumab plus EP significantly improved PFS compared with placebo plus EP as first-line therapy for patients with ES-SCLC. No unexpected toxicities were seen with pembrolizumab plus EP. These data support the benefit of pembrolizumab in ES-SCLC.


Related Papers

No related papers found

Powered by citation graph analysis